1999
DOI: 10.1093/jnci/91.14.1211
|View full text |Cite
|
Sign up to set email alerts
|

Potential Drugs Against Cervical Cancer: Zinc-Ejecting Inhibitors of the Human Papillomavirus Type 16 E6 Oncoprotein

Abstract: We have described assay systems to identify compounds, such as 4,4'-dithiodimorpholine, that can potentially interfere with the biology and pathology of HPV. These assay systems may be useful in the development of drugs against cervical cancer, genital warts, and asymptomatic infections by genital HPVs.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
52
0

Year Published

2000
2000
2020
2020

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 77 publications
(54 citation statements)
references
References 40 publications
1
52
0
Order By: Relevance
“…1A). There are four zinc-binding motifs (grey boxes), Cys-X-X-Cys, that form two hypothetical fingers involving zinc binding (3,30). Domains are depicted below the 16E6 diagram.…”
Section: Vol 77 2003 Nuclear Signals Of 16e6 13243mentioning
confidence: 99%
“…1A). There are four zinc-binding motifs (grey boxes), Cys-X-X-Cys, that form two hypothetical fingers involving zinc binding (3,30). Domains are depicted below the 16E6 diagram.…”
Section: Vol 77 2003 Nuclear Signals Of 16e6 13243mentioning
confidence: 99%
“…However, cancerous cells may consume the zinc present in the circulation for tumor growth and maintain membrane integrity. 43 This might be a possible reason for the depletion of zinc in breast cancer. The increased ratio of Cu/ Zn is due to the significant decrease in Zn and concomitant increase in copper.…”
Section: Discussionmentioning
confidence: 99%
“…Several strategies targeting E6 or the E6/E6-AP complex have been developed, exemplified by cytotoxic drugs, a zinc-ejecting inhibitor of the viral E6 oncoprotein, an E6-AP mimetic epitope peptide (mimotope), an anti-E6 ribozyme, peptide aptamers targeting the viral E6 oncoprotein, siRNAs of the viral E6 oncogene, and combinations of all these therapies [45-53]. A new strategy is to induce viral E6 and E7 instability by using HSP90 and GRP78 inhibitors for the treatment of cervical cancer [54].…”
Section: Therapeutics Against Hpvsmentioning
confidence: 99%